



Great News!!!

HUMIRA® is Now Approved in Canada for the Treatment of Moderate-to-Severe Plaque Psoriasis

Psoriasis affects over 600,000 Canadians, typically aged between 15 and 25. It is a non-contagious, chronic autoimmune disease that causes the body to attack itself. The most obvious physical symptom of the condition is raised, inflamed, scaly, red skin lesions known as plaques, which may crack and bleed. Psoriasis is more than painful skin lesions; it can lead to poor self-image, social isolation and depression, and may be associated with other health conditions, including psoriatic arthritis.

HUMIRA was shown to offer remarkable skin clearance (up to 90 percent) and long-term disease control, bringing new hope to psoriasis sufferers.

Psoriasis is the fifth approved indication for HUMIRA in Canada. This reflects Abbott's strong commitment to immunology.

